home / stock / fblg / fblg news

FBLG News and Press, FibroBiologics Inc. From 02/10/26

Stock Information
Company Name: FibroBiologics Inc.
Stock Symbol: FBLG
Market: NASDAQ
Website: fibrobiologics.com
Menu
FBLG FBLG Quote FBLG Short FBLG News FBLG Articles FBLG Message Board
Get FBLG Alerts

News, Short Squeeze, Breakout and More Instantly...
FBLG - FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

HOUSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chron...
FBLG - FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chron...

FBLG - FibroBiologics to Present at the DealFlow Discovery Conference

HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...

FBLG - FibroBiologics CEO Issues Letter to Shareholders

HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...
FBLG - FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chron...

FBLG - FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...

FBLG - FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...
FBLG - FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

HOUSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chron...

FBLG - FibroBiologics announces $1.7M registered direct offering

2025-12-15 08:56:36 ET More on FibroBiologics FibroBiologics announces payoff of outstanding debt FibroBiologics raises $4M in gold-funded registered direct offering Seeking Alpha’s Quant Rating on FibroBiologics Historical earnings data for FibroBiolo...

FBLG - FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chron...
Previous 10 Next 10